Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals is a specialty biopharmaceutical company focused on reinventing and optimizing existing medications to address unmet medical needs. The company primarily utilizes the FDA's 505(b)(2) regulatory pathway, which allows for the approval of new formulations or applications of previously approved drugs, significantly reducing development time, costs, and risks compared to new chemical entities. The company's strategy involves identifying established molecules with known safety profiles and applying proprietary technological innovations to improve their efficacy, safety, or ease of administration. Hyloris has built a broad portfolio across diverse therapeutic areas, including cardiovascular health, pain management, and CNS disorders, with a focus on high-value hospital products and specialty medicines.